stock
RGEN · REPLIGEN CORP
What REPLIGEN CORP reports to the SEC, read from its filings.
Open in the appPrice
The live RGEN price and today's change.
Sign in to see thisChart
Thirty days of daily bars, with signal levels drawn on them.
Sign in to see thisSignals
The latest signal group Nakagai's scanner recorded on RGEN.
Sign in to see thisOptions positioning
Gamma exposure levels from the options market.
Sign in to see thisTechnicals
Trend, momentum and volatility gauges per timeframe.
Sign in to see thisWhat it is
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Filer (SEC EDGAR)
- EDGAR filing index
- Shares outstanding
- 56,435,621 as of 2026-07-24 (XBRL frame CY2026Q2I)
Key stats
Valuation
- P/E
- Locked
- P/S
- Locked
- P/B
- Locked
- Enterprise value
- Locked
- EV/EBIT
- Locked
- FCF yield
- Locked
Margins
- Gross
- —
- Operating
- 8.2%
- Net
- 5.3%
Returns
- ROE
- 2.0%
- ROA
- 1.4%
Health
- Current ratio
- 9.1x
- Debt/equity
- 0.3x
Deep value
- NCAV
- $362.41M
- NCAV per share
- $6.42
- Price/NCAV
- Locked
- NNWC
- -$19.78M
- NNWC per share
- -$0.35
- Price/NNWC
- Locked
Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.
Sign in to see thisDebt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue | Gross profit | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | $204.13M | — | $13.98M | $5.01M | 10-Q filed 2026-07-29 |
| 2026-03-31 | $194.25M | — | $15.94M | $8.33M | 10-Q filed 2026-05-06 |
| 2025-12-31 | $197.91M | — | $17.87M | $13.29M | 10-K filed 2026-02-26 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. |
| 2025-09-30 | $188.81M | — | $16.82M | $14.91M | 10-Q filed 2025-11-04 |
| 2025-06-30 | $182.37M | — | $13.90M | $14.87M | 10-Q filed 2026-07-29 |
| 2025-03-31 | $169.17M | — | $6.58M | $5.83M | 10-Q filed 2026-05-06 |
| 2024-12-31 | $167.55M | — | -$36.50M | -$33.87M | 10-K filed 2026-02-26 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. |
| 2024-09-30 | $154.87M | — | -$7.83M | -$654,000 | 10-Q filed 2025-11-04 |
- Assets
- $2.95B
- Equity
- $2.11B
Balance as of 2026-06-30.
Ten years
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| 2025-12-31 | $738.26M | $55.17M | $48.89M | $93.90M |
| 2024-12-31 | $634.44M | -$35.11M | -$25.51M | $149.72M |
| 2023-12-31 | $632.36M | $47.70M | $35.60M | $77.70M |
| 2022-12-31 | $801.54M | $224.67M | $185.96M | $87.25M |
| 2021-12-31 | $670.53M | $167.25M | $128.29M | $51.93M |
| 2020-12-31 | $366.26M | $69.82M | $59.93M | $40.17M |
| 2019-12-31 | $270.25M | $36.08M | $21.41M | $48.71M |
| 2018-12-31 | $194.03M | $25.99M | $16.62M | $22.14M |
| 2017-12-31 | $141.24M | $14.01M | $28.35M | $12.00M |
| 2016-12-31 | $104.54M | $15.97M | $11.68M | $3.20M |
Company filings
1 offering filing in 12 months
events
Acquisition or sale completed, Regulation FD disclosure
Acquisition or sale completedRegulation FD disclosureOct 68-KExecutive or director change
Executive or director changeSep 158-KOther event
Other eventSep 88-KResults
ResultsJul 288-KMaterial agreement, Results, Regulation FD disclosure, Other event
Material agreementResultsRegulation FD disclosureOther eventJul 228-KShareholder vote results
Shareholder vote resultsMay 158-K
5% owners ()
T. Rowe Price Associates, Inc.
Stake update
Vanguard Capital Management
Passive stake
The Vanguard Group
Stake update
T. Rowe Price Associates, Inc.
Stake update
Roy T. Eddleman Living Trust
Stake update
Insiders, politicians and funds
Insider trades, last 90 days
Loeillot Olivier
Chief Executive Officer, Director
Sale$2,459,740Sep 25, 4:09 PM ET
Loeillot Olivier
Chief Executive Officer, Director
Sale$976,680Sep 22, 4:07 PM ET
Loeillot Olivier
Chief Executive Officer, Director
Sale$503,507Sep 8, 4:13 PM ET
Loeillot Olivier
Chief Executive Officer, Director
Sale$976,680Aug 21, 4:06 PM ET
Garland Jason K
CFO
Sale$79,500Jul 17, 4:40 PM ET
Politician trades, last 90 days
No politician trades filed in the last 90 days.
Funds
- Maverick Capital
Period Tue 30 Jun 2026
2.4%Added - Weitz Investment Management
Period Tue 30 Jun 2026
0.4%Added - Duquesne Family Office
Period Tue 30 Jun 2026
0.2%New - Point72
Period Tue 30 Jun 2026
0.0%Trimmed
News
Stories that named RGEN, and the market events around them.
Sign in to see thisBoard
Recent signals
Signals open up here once a member has posted about RGEN.
Signals are informational.
Posts · 0
No posts yet.
nakagai
Signals on RGEN come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Members post on the RGEN board